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ABSTRACT
Background: Invasive mold infections in children with hematological malignancies are associ-
ated with high mortality rates. The use of combination antifungal therapy in cases with a severe 
clinical course is increasing, although information on the efficacy and safety of this approach is 
limited. 
Methods: We present a case series of 13 children affected by hemato-oncological disorders who 
received combination antifungal therapy for invasive mold infections at our center (Pediatric 
Hematology, San Gerardo Hospital, Monza, Italy) from 2011 to 2016, with the aim of describing 
their clinical characteristics, types of infections, treatment regimens, clinical outcomes, and treat-
ment safety. Medical records were retrospectively reviewed in order to describe patients’ charac-
teristics. 
Results: Combination antifungal therapy included liposomal amphotericin associated with 
caspofungin (5/13, 38.4%), voriconazole (5/13, 38.4%), or posaconazole (3/13, 23.1%). The 12-
week treatment response rate was 69.2% (6/13 patients showed complete response, 3/13 partial re-
sponse). The crude mortality was 30.7% (4/13): half was related to invasive mold infections (2/13, 
15.38%) and half to disease progression (2/13, 15.38%). Overall, treatment was well tolerated, and 
we did not observe any permanent discontinuation of antifungals due to related side effects. 
Conclusions: In our experience, combination antifungal therapy seems to be a safe option in im-
munocompromised children with invasive mold infections. Well-designed studies are needed to 
confirm the safety of this approach and to better understand its efficacy in the pediatric setting.
Keywords: antifungal therapy; mold; hematological malignancies
BACKGROUND
Invasive mold infections (IMI) represent a major cause of morbidity and mortality among pedi-
atric patients affected by hematological malignancies and are often associated with poor clinical 
outcomes despite the use of active antifungal drugs [1-6]. 
Controversies exist over the benefit of using a combination antifungal treatment (CAT) in this 
patient population. In particular, the attempt of improving the efficacy of the treatment is often 
balanced by concerns of a decreased safety due to cumulative toxicities. Evidence about the role 
of CAT for the treatment of IMI is scarce in the adult population and even more limited in the 
pediatric setting. In particular, well-designed studies on the use of CAT in immunocompromised 
children are lacking, and the current knowledge on this topic mainly relies on retrospective and 
prospective cohorts [1-6]. In this scenario, any experience of treating IMI with CAT in children 
may help clinicians to gain knowledge in this field and hopefully serve as a starting point for 
further larger studies. Hence, we report our real-life case series on the use of CAT in the pediatric 
setting.
METHODS
We present a case series of IMI in children affected by hematological malignancies treated with 
CAT at the Hematology-Oncology and Bone Marrow Transplantation Unit, Pediatric Depart-
ment, San Gerardo Hospital, Monza, Italy, from 2011 to 2016, with the aim of describing their 
clinical characteristics, types of infections, clinical outcomes, and treatment safety. 
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All patients with diagnosis of possible, probable, or proven IMI as defined by the European Or-
ganization for Research and Treatment of Cancer (EORTC) criteria were included [7]. Medical 
records were retrospectively reviewed to describe patients’ characteristics, outcomes, and treat-
ment safety. 
For each patient we recorded the clinical outcome 12 weeks after diagnosis of IMI: among living 
patients we distinguished those with complete response to treatment (full recovery) and those 
with partial response (major improvement of symptoms and radiologic findings).
RESULTS
During the study period (2011-2016) 13 cases of IMI in pediatric patients affected by hematolog-
ical malignancies were treated with CAT at our Center. Eight of 13 patients (61.5%) were males 
and the mean age was 10 years (3 months-16 years) For demographic characteristics of patients 
see Table 1.
Invasive Mold Infections and Disease Site Involvement
Five patients (38.5%) met EORTC criteria for proven IMI. In particular, Absidia Corymbifera and 
another untyped Mucorales grew on the orbital biopsies of 2 patients with rhino-orbital-cerebral 
mucormycosis while Aspergillus flavus grew on the orbital biopsy of 1 patient with rhino-cerebral 
and pulmonary aspergillosis; Fusarium subglutinans was isolated from blood cultures of a fourth 
patient with disseminated fusariosis with cutaneous involvement. A fifth patient had hyphae on 
a liver biopsy establishing the diagnosis of proven IMI, probable Aspergillosis (no results from 
cultures were available) with hepatosplenic and pulmonary involvement.
Five more patients had probable pulmonary aspergillosis, documented by Galactomannan an-
tigen assay and compatible clinical-radiological signs. These patients all had pulmonary disease 
with 3 of them also having central nervous system (CNS) involvement and 1 having liver involve-
ment.
The remaining 3 patients had possible pulmonary aspergillosis with 1 also having hepatosplenic 
involvement.
Of note, the diagnosis of probable or possible hepatosplenic involvement was established by im-
aging. Characteristics of IMI are summarised in Table 2.
Hematological Malignancies 
Ten patients developed IMI while receiving chemotherapy and 3 following hematopoietic stem 
cell transplantation (HSCT). 
Among patients receiving chemotherapy, 7/10 were affected by acute lymphoblastic leukemia 
(ALL) (of whom 5 in front-line therapy and 2 in first-relapse), 1/10 was affected by first-relapsed 
acute myeloid leukemia (AML), 1/10 by first-relapsed non-Hodgkin lymphoma (NHL) and 1/10 
by haemophagocitic lymphohistiocytosis (HLH) in front-line treatment.
All were in the most intensive phases of chemotherapy (6 in the induction and 4 in the re-induc-
tion phase), essentially with anthracyclines, vincristine, steroids, antimetabolites, and alkylating 
agents.
Pathogens and Immunity - Vol 4, No 2
www.PaiJournal.com
183
Table 1. Demographics and characteristics of hematological malignancies of 13 patients 
with invasive mold infections
Patient
Gender 
and Age 
(years)
Ethnicity
Haematological 
Disease 
Time of 
Occurrence
Haematological 
Treatment
Neutropenia 
(N/mm3)
GVHD
Steroid 
(prednisone 
equivalent)
1 M, 9 White Relapsed ALL
Induction 
Therapy
CT < 100 No
> 2 mg/kg 
day
2 M, 14 White Relapsed ALL
allo-SCT 
(day+10)
CyA, MTX, ATG < 100 No No
3 F, 5 White ALL front line
Induction 
Therapy
CT < 500 No
> 2 mg/kg 
day
4 F, 8 White ALL front line
Induction 
Therapy
CT < 100 No
> 2 mg/kg 
day
5 M, 13 White ALL front line
Induction 
Therapy
CT < 100 No
> 2 mg/kg 
day
6 M, 16 White ALL front line
Induction 
Ttherapy
CT > 500 No
> 2 mg/kg 
day
7 M, 12 White NHL relapse/salvage CT <100 No
> 2 mg/kg 
day
8 F, 3 White Relapsed ALL relapse/salvage CT < 100 No
< 2 mg/kg 
day
9 M, 15 White Relapsed AML relapse/salvage CT < 100 No
> 2 mg/kg 
day
10 M, 16 Asian CML
allo-SCT 
(day+200)
MMF, PDN 500-1000 Yes
> 2 mg/kg 
day
11 F, 12 White ALL front line
Induction 
Therapy
CT < 100 No
> 2 mg/kg 
day
12 M, 10 Asian Relapsed NHL
allo-SCT 
(day+120)
CyA, PDN < 500 No
< 2 mg/kg 
day
13
F, 90 
days
African HLH
Induction 
Therapy
DXM, VP16, 
ATG
< 500 No
> 2 mg/kg 
day
Abbreviations: M = Male; F = Female; ALL = Acute Lymphoid Leukemia; NHL = Non-Hodgkin Lymphoma; 
AML = Acute Myeloid Leukemia; CML = chronic myeloid leukemia; HLH = haemophagocitic hystiocitosis; 
SCT = Stem Cells Transplantation; CyA = Cyclosporine A; MTX = methotrexate; ATG = anti-thymocyte globulin; 
CT = Chemotherapy; MMF = mycofenolate mofetil; PDN = prednisone; DXM = dexamethasone; VP16 = etoposide; 
N = neutrophils; GVHD = Graft Versus Host Disease
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Table 2. Characteristics of invasive mold infections (IMI) and patients’ outcome.
Patient
EORTC 
Classification
Species Site of IMI
Concurrent 
Infections
Combination 
Therapy
Outcome and 
12-weeks Response
1
Possible 
aspergillosis
-
lung, liver, 
spleen
coronavirus 
229E/NL63
L-AMB + 
caspofungin
Favourable (CR)
2
Probable 
aspergillosis
- lung
BSI S.mitis/R. 
mucilaginosa
L-AMB + 
caspofungin
Favourable (PR)
3
Probable 
aspergillosis
- lung, CNS RSV B
L-AMB + 
voriconazole
Failure, death due to 
IMI
4
Proven IMI 
(probable 
aspergillosis)
-
lung, liver, 
spleen
No
L-AMB + 
caspofungin
Favourable (CR)
5
Probable 
aspergillosis
- lung, CNS, liver
BSI S. 
Epidermidis
L-AMB + 
voriconazole
Favourable (PR)
6
Proven 
mucormycosis
Absidia 
corymbifera
rinocerebral No
L-AMB + 
posaconazole
Favourable (CR)
7
Proven 
mucormycosis
Untyped 
mucorales
rhino-orbito-
cerebral
No
L-AMB + 
posaconazole
Favourable (CR)
8
Proven 
fusariosis
Fusarium 
subglutinans
BSI, skin
rinovirus 
A/B/C
L-AMB + 
voriconazole
Favourable (CR)
9
Possible 
aspergillosis
- lung No
L-AMB + 
posaconazole
Failure, death due to 
HD
10
Probable 
aspergillosis
- lung, CNS CMV viremia
L-AMB + 
voriconazole
Failure, death due to 
IMI
11
Probable 
aspergillosis
- lung
BSI P. 
aeruginosa
L-AMB + 
caspofungin
Favourable (PR)
12
Possible 
aspergillosis
- lung
VZV Zoster 
C5-C7
L-AMB + 
voriconazole
Favourable (CR)
13
Proven 
aspergillosis
Aspergillus 
flavus
lung, 
rhinocerebral
K.pneumoniae 
UTI
L-AMB + 
caspofungin
Failure, death due to 
HD
Abbreviations: EORTC: European Organization for Research and Treatment of Cancer IMI = Invasive 
Mold Infections; CNS = Central Nervous System; BSI = Bloodstream Infection; RSV = Respiratory Syncitial 
Virus; CMV = Cytomegalovirus; VZV = Varicella Zoster Virus; UTI = Urinary Tract Infection; L-AMB = li-
posomal amphotericin B; CR = Complete Response; PR = Partial Response; HD = Hematological Disease.
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In the second group patients received HSCT for relapsed NHL, relapsed ALL, and chronic my-
eloid leukemia. All of them received a myeloablative conditioning regimen. One patient had liver 
graft-versus-host-disease and was receiving treatment with cyclosporine, mycophenolate, and 
steroids.
All patients were neutropenic at the time of the diagnosis of IMI: in particular  8/13 patients 
(62%) had neutrophil count < 100/μL, 3/13 patients (23%) had neutrophil count within 100-500/
μL and 2/13 patients within 501-1000/μL. Severe neutropenia (defined as neutrophil count < 500/
mm3) preceding the diagnosis of IMI lasted on average 10.9 days (5-26 days). 
Moreover, 12/13 patients were receiving steroids (7 prednisolone, 2 dexamethasone, 3 methyl-
prednisolone), of whom 83% were receiving high doses (prednisone equivalent > 2mg/Kg/dai-
ly). All transplanted patients were also undergoing prophylaxis with cyclosporine. According to 
internal guidelines, 7/13 patients were receiving antifungal prophylaxis for high-risk underlying 
disease, 4 with liposomal amphotericin (L-AMB), 2 with fluconazole, one with posaconazole. 
Characteristics of hematological malignancies are summarised in Table 1
Treatment
Ten out of 13 patients received CAT as salvage treatment while the remaining 3/13 received CAT 
as first-line approach: in the latter group, 2 were undergoing prophylaxis with L-AMB twice/
weekly and one with fluconazole (6-10 mg/Kg/daily) when diagnosis of IMI was established. 
Combination regimens included L-AMB associated with caspofungin (5/13, 38.4%), posacon-
azole (3/13, 23.1%), and voriconazole (5/13, 38.4%). Ten patients received L-AMB at 3-5 mg/Kg/
daily while 3 patients with CNS involvement received 5-10 mg/Kg/daily. Caspofungin was used 
at the dosage of 50 mg/m2/daily while the dosage of posaconazole and voriconazole was titrated 
according to their plasmatic concentrations (Therapeutic Drug Monitoring, TDM). Caspofungin 
was chosen as the second antifungal agent in 5 patients with invasive aspergillosis (IA), while 
posaconazole was given to 2 patients with rhino-orbital-cerebral mucormycosis, and to 1 patient 
with possible IA who was already receiving L-AMB prophylaxis.; voriconazole was chosen as the 
second agent in 3 patients with CNS aspergillosis, in 1 patient with pulmonary aspergillosis and 
in 1 patient with invasive fusariosis.The mean duration of CAT was 40 days (5-98 days). Maxillo-
facial surgery was required in cases of rhino-orbital-cerebral mucormycosis and aspergillosis. For 
treatment see Table 3.
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Table 3. Combination antifungal therapy regimens.
Patient
Monotherapy 
Before 
Combination
Duration of 
Monotherapy 
(Days)
Combination 
Therapy
Duration of 
Combination 
Therapy 
(Days)
Maintainance 
Therapy
Duration of 
Maintainance 
Therapy 
(Months)
Surgery
1 L-AMB 11
L-AMB + 
caspofungin
37
Voriconazole; 
L-AMB 
posaconazole§
12 No
2 L-AMB 12
L-AMB + 
caspofungin
48 L-AMB > 18 No
3 L-AMB 2
L-AMB + 
voriconazole
11 [NA] [NA] No
4 L-AMB 21
L-AMB + 
caspofungin
41 Voriconazole 10 No
5 L-AMB 11
L-AMB + 
voriconazole
49 Voriconazole 15 No 
6 voriconazole 3
L-AMB + 
posaconazole
92 Posaconazole 48 Yes 
7 L-AMB 12
L-AMB + 
posaconazole
98
L-AMB 
posaconazole§
4 Yes 
8 L-AMB 6
L-AMB + 
voriconazole
10 Voriconazole 1,5 No 
9 No -
L-AMB + 
posaconazole
28 [NA] [NA] No 
10 No -
L-AMB + 
voriconazole 
5 [NA] [NA] No 
11 No -
L-AMB + 
caspofungin
36 Voriconazole 12 No 
12 L-AMB 24
L-AMB + 
voriconazole
17 Voriconazole 48 No 
13 L-AMB unknown
L-AMB + 
caspofungin
50 [NA] [NA] Yes 
(*) Including laboratory investigations 
Abbreviations: L-AMB = liposomal amphotericin B; NA = Non Applicable. §consecutive regimens
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Outcome 
We recorded the outcome 12 weeks after the diagnosis of IMI. Overall mortality was 30.7% 
(4/13). Two deaths were related to progression of CNS aspergillosis and 2 to progression of the 
underlying malignancy. The 12-week overall response was 69.2%: 6 patients showed complete re-
sponse (one reporting monocular blindness after surgical curettage of the orbit), while 3 showed 
partial response (see Table 2).
Safety
Toxicities during CAT were classified according to Common Terminology Criteria for Adverse 
Events [8]. Overall, CAT was well tolerated. Seven patients reported transitory altered liver tests, 
including bilirubin, transaminases, and gamma-glutamyltransferase (GGT). In particular 2 
patients reported a grade 1 increase of liver markers (both of GGT and one of transaminases), 2 
patients reported a grade 2 increase of bilirubin with 1 of them also reporting a grade 2 increase 
of GGT and the other reporting a grade 2 increase of transaminases. The remaining 3 patients 
reported a grade 3 increase of GGT with 2 of them also reporting a grade 3 increase of transami-
nases.
Moreover, 6 patients reported acute kidney injury (AKI) and 6 hypokalemia. Markers of liver 
dysfunction were high in 4 patients treated with the combination L-AMB + voriconazole and in 3 
patients treated with the combination L-AMB + caspofungin, of note, among these patients 2 also 
had hepatic involvement by the fungal infection. 
In 1 case AKI led to L-AMB dose reduction, in another patient altered liver tests led to tempo-
rary discontinuation of CAT that was safely reintroduced 24 hours later, after improvement of the 
hepatic function. No definitive discontinuation occurred (see Table 4).
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Table 4. Toxicities attributed to combination antifungal therapy.
Patient Hepatobiliary Toxicity* Renal Toxicity*
Treatment Discontinuation or 
Modification
1 Liver test increase grade 2
2 Liver test increase grade 3 AKI grade 1
3 Liver test increase grade 3
CAT temporary 
discontinuation (24 hours) 
4 Liver test increase grade 3 Hypokalemia grade 2
5 AKI grade 2 Hypokalemia grade 2
6 AKI grade 2
7 Liver test increase grade 2 AKI grade 2 L-AMB dose reduction
8 Hypokalemia grade 2
9 Liver test increase grade 1 Hypokalemia grade 2
10 AKI grade 1 Hypokalemia grade 2
11 Hypokalemia grade 2
12 Liver test increase grade 1 AKI grade 1
13
Abbreviations: L-AMB = liposomal amphotericin B; AKI = Acute Kidney Injury; CAT = combination antifungal 
therapy.
DISCUSSION AND CONCLUSIONS
Despite an improvement in the outcome of IMI in children with hematological malignancies hav-
ing been reported by recent studies compared to studies from the last few decades [9-11], mortali-
ty is still high in this patient population. In particular, recent studies on children with hemato-on-
cological disorders and IMI treated with different regimens report crude mortality rates ranging 
from 30% to 52.5% [1-6], in line with our case series, in which the overall death rate was 30.7%. 
CAT is often chosen as a strategy to improve the outcome in those cases of IMI with severe clini-
cal course: its main goal is to widen the spectrum of therapy, to lower the risk of resistance and to 
exploit the synergism between some drugs.
Few randomized controlled studies have been published on adult patients assessing the role of 
CAT compared to monotherapy in the clinical setting, and there is still very little evidence about 
the efficacy and safety of this approach [12]. If evidence is limited in the adult population, it is 
even scarcer in the pediatric setting. 
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The Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiolo-
gy and Infectious Diseases (ESCMID) guidelines still recommend monotherapy for the majority 
of IMI. Combination therapy with echinocandins + L-AMB or azoles are listed as an alternative 
in salvage therapy for IA while the association of L-AMB with posaconazole or caspofungin is 
regarded as an option for refractory mucormycosis [13-15]. 
Despite the lack of well-designed trials assessing the efficacy and safety of this approach, combi-
nation antifungal regimens are widely used in real-life pediatric settings as reported by several 
studies. Monocentric surveys on IMI in immunocompromised children reported the use of com-
bination therapy in a percentage of cases ranging from 32% to 92% [2-4]. A multicenter cohort 
study performed by Burgos et al, involving 6 US pediatric centers, reported the use of combina-
tion regimens in up to 80% of IMI [1]. Moreover, a multicenter international prospective cohort 
study on mucormycosis by Pana et al reported the use of first-line combination therapy in 53% of 
cases [6].
Similar to our findings, several pediatric series report the use of CAT mainly as salvage treatment 
[5, 16-19], but also as first-line, especially in patients receiving anti-mold prophylaxis [5]. 
In a recent Italian multicenter study on 127 invasive fungal infections in hemato-oncological 
pediatric patients, up to 45/126 (36%) episodes were treated with antifungal combinations as 
initial therapy and the author speculates that this choice was driven by the more severe clinical 
conditions of these patients [19]. Furthermore, in the international multicenter observational co-
hort study by Wattier et al on 131 IMI in children affected by hematological neoplasms, first-line 
combination therapy was used in 53% of cases and, similar to our findings, it was mainly used in 
patients who were already receiving anti-mold prophylaxis possibly due to concerns about pro-
phylaxis-induced resistance [5].
Overall response to combination therapy in our case series was 69.2% with an IMI associated 
mortality of 15.4%, and no definitive discontinuations related to toxicity occurred. 
Data from the pediatric literature on CAT report similar rates of favorable responses and toxicity, 
although the heterogeneity of patient populations and antifungal regimens of such studies, to-
gether with different underlying neoplasms and fungal infections included, prevent from drawing 
any evidence about the superiority of CAT over monotherapy in relation to outcome and safety 
[3, 16-18]. Indeed, outcomes reported in our case series are not different from outcomes reported 
in the literature in children treated with monotherapy, and overall there is paucity of well-de-
signed studies aimed at comparing mortality in pediatric patients treated with monotherapy 
versus combination therapy.
In particular, only 1 prospective study from Wattier et al compared outcomes and safety of 131 
children with IMI (75% IA) treated with CAT (70/131, 53%) or monotherapy (61/131, 47%) [5]. 
In that study, no favorable association between CAT and outcome was found; conversely, CAT 
was associated with increased toxicity. However, the study had several limitations, indeed ac-
knowledged by the authors, in particular the heterogeneity of CAT. Furthermore, the ineffective-
ness of CAT on the outcome was hampered by several confounding factors (with the more se-
verely ill patients being more likely to receive more aggressive therapy but also being more likely 
to experience poor outcomes), and the association of CAT with toxicity could be a result of the 
underlying severity of the illnesses.
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In our center, the combination of L-AMB with caspofungin was used for IA as the main CAT. 
This combination is synergic in vitro [20] and showed promising clinical results among both 
adults [12] and children [18]. All but 1 patient (4/5) treated with this association survived. The 
fifth died due to the progression of the underlying malignancy; of note, this patient was the only 
one in this group to have aspergillosis with rhino-cerebral involvement. 
Conflicting results are available in the literature about the association of L-AMB with azoles. 
Some in vitro studies have reported antagonism between the 2 drugs [21] while this combina-
tion has proven to be effective and associated with improved outcomes in animal models of CNS 
aspergillosis [22-24]. Although evidence is controversial, many real-life studies report the use of 
this combination in clinical practice in the pediatric setting [4, 5, 19]. In our case series, the com-
bination of L-AMB with voriconazole was mainly used to treat CNS aspergillosis. Among these 
patients, mortality rate was high: Of note, CNS aspergillosis is historically associated with poor 
outcome [13] and studies are needed to establish the best treatment. 
The intrinsic resistance of Fusarium species to most antifungals leads to high mortality rates 
in patients with invasive fusariosis. Despite the concerns about in vitro antagonism between 
polyenes and azoles, some studies have shown in vitro synergism of voriconazole and L-AMB 
against Fusarium [25]. Based on such studies and on few clinical reports of success in the treat-
ment of invasive fusariosis with the association of L-AMB with voriconazole, some authors sup-
port CAT for fusariosis [26-29]. In this case series 1 patient with invasive fusariosis was success-
fully treated with L-AMB associated with voriconazole.
Lastly, the association of L-AMB with caspofungin or posaconazole is associated with encour-
aging results in the salvage treatment of mucormycosis [14, 15]. We have described 2 cases of 
mucormycosis with rhino-cerebral and orbital involvement successfully treated with L-AMB in 
association with posaconazole and surgery. A recent study from Greece by Pana et al reported the 
use of CAT in 26/63 children with invasive mucormycosis [6]; however, the impact of CAT on 
survival could not be estimated due to the small patient population. 
In the present age, cases of IMI in immunocompromised children affected by hematological 
malignancies are still associated with high morbidity and mortality. Through our case series we 
report our real-life experience in treating IMI with CAT at our pediatric center. Given the merely 
descriptive purpose of our report which lacks a statistical analysis, we are aware that our work 
will not provide enough evidence for further recommendations about efficacy and safety of CAT 
in children with hemato-oncological malignancies affected by IMI. However, given the scarcity 
of data about this topic in the literature together with the rarity of such infections in this patient 
population yet associated with a severe prognosis, we believe that even isolated experiences from 
single-center institutions can add useful knowledge to this field.
While waiting for well-designed controlled studies, CAT might be regarded as a possible ap-
proach for IMI in children with hemato-oncological diseases; in particular, the use of CAT could 
be considered early when prognosis is not favorable.
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